What is Lantheus Holdings's neuraceq — revenue?

Lantheus Holdings (LNTH) reported neuraceq — revenue of $35.44M in Q1 2026.

What does neuraceq — revenue mean?

This metric represents the total gross revenue generated from the sale or licensing of the Neuraceq diagnostic product, excluding any taxes collected from customers. It serves as a key indicator of market adoption and commercial performance for this specific radiopharmaceutical diagnostic agent within the company's oncology portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the product in the diagnostic imaging market.

Lantheus Holdings LNTH Neuraceq — Revenue

Other product segments

Oncology

$240.92M—

PYLARIFY

$240.92M-6.5%

Cardiology

$84.63M—

Definity

$84.63M+6.8%

Neurology

$35.44M—

Strategic Partnerships And Other

$16.34M+52.1%

Licenseand Royalty Revenues

$7.48M+28.0%

SPECT Business

$0—

Similar metrics at other companies

PTCTProduct — Revenue

$225.57M+47.0%

AXSMProduct — Revenue

$189.4M+57.4%

LQD

LQDAProduct — Revenue

$129.88M—

CYTKNet Product Revenue — Revenue

$4.79M—

ALKSProduct — Revenue

$338.11M+38.3%

JAZZProduct sales, net — Revenue from Contract with Customer, Excluding Assessed Tax

$1.03B+22.1%

Other financials

Income statement

See full

Revenue$377.3M+1.2%

Gross profit$230.9M-2.9%

Operating income$81.3M-20.3%

Net income$118.4M+62.3%

EPS (diluted)$1.80+76.5%

Balance sheet

See full

Cash & equivalents$500.3M-46.8%

Total debt$627.9M+1.8%

Total equity$1.2B+4.1%

Total assets$2.3B+14.2%

Cash flow

See full

Operating cash flow$125.1M+16.3%

CapEx$3.2M-63.0%

Free cash flow$121.9M+23.3%

Valuation

See full

Market cap$6.76B-26.3%

Enterprise value$6.89B-20.5%

P/E24.2×-10.2×

P/S4.4×-1.6×

Profitability

See full

Gross margin60.5%-3.6pp

Operating margin18.8%-10.7pp

Net margin18%+0.7pp

FCF margin24.4%-6.4pp

Returns & leverage

See full

Return on equity23.5%-1.7pp

Debt / equity0.5×0.0×

Current ratio2.8×-2.9×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Lantheus Holdings’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lantheus Holdings's neuraceq — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lantheus Holdings's neuraceq — revenue?: Lantheus Holdings (LNTH) reported neuraceq — revenue of $35.44M in Q1 2026.
What does neuraceq — revenue mean?: This metric represents the total gross revenue generated from the sale or licensing of the Neuraceq diagnostic product, excluding any taxes collected from customers. It serves as a key indicator of market adoption and commercial performance for this specific radiopharmaceutical diagnostic agent within the company's oncology portfolio. Tracking this revenue stream allows investors to evaluate the growth trajectory and competitive positioning of the product in the diagnostic imaging market.